Am­gen's Ote­zla bags ex­pand­ed FDA nod in pso­ri­a­sis; I-Mab CEO hits the ex­it amid shake­up at Chi­nese firm

Just a few weeks af­ter Ote­zla notched a Phase III win and hit all pri­ma­ry and sec­ondary end­points for a tri­al in gen­i­tal pso­ri­a­sis, Am­gen’s block­buster drug Ote­zla gets yet an­oth­er OK from the FDA.

The biotech an­nounced yes­ter­day the FDA ap­proved Ote­zla (apremi­last) for an ex­pand­ed in­di­ca­tion: the treat­ment of adult pa­tients with plaque pso­ri­a­sis who are can­di­dates for pho­tother­a­py or sys­temic ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.